Related Experiment Videos
Clinical management of prolactinomas
1Department of Endocrinology and Diabetes, Northern General Hospital, Sheffield, UK.
Summary
Dopamine agonists are the primary treatment for prolactinomas, effectively normalizing prolactin levels and restoring gonadal function in most patients. Surgery is reserved for specific cases, while monitoring may be an option for select individuals with small tumors.
Area of Science:
- Endocrinology
- Oncology
- Neurosurgery
Background:
- Prolactinomas are common pituitary tumors causing hormonal imbalances like amenorrhea, galactorrhea, and hypogonadism.
- Hyperprolactinemia can lead to reduced bone mineral density, potentially irreversible.
- Tumor size (micro vs. macro) influences clinical presentation and treatment approach.
Purpose of the Study:
- To review the management strategies for prolactinomas.
- To compare the efficacy and safety of different treatment modalities.
- To provide guidance on monitoring and long-term therapy.
Main Methods:
- Review of current medical literature on prolactinoma treatment.
- Analysis of outcomes for dopamine agonist therapy, surgery, and observation.
- Comparison of different dopamine agonists (cabergoline, bromocriptine) and alternatives (quinagolide).
Main Results:
- Dopamine agonists normalize prolactin in 80-90% of microprolactinomas and shrink 80% of macroprolactinomas.
- Trans-sphenoidal surgery is curative in 60% of microprolactinomas but carries risks.
- Cabergoline is generally preferred over bromocriptine due to better efficacy and tolerability.
Conclusions:
- Dopamine agonists are the first-line treatment for most prolactinomas.
- Surgery is an option for drug-intolerant/resistant cases or specific tumor types.
- Long-term monitoring and potential drug withdrawal should be considered after successful treatment.